Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.56 |
| ▸ | HTR3A | P46098 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6161213 | 0.95 | ALDH1A1 (0.62) | ALDH1A1SMN1; SMN2GAAMAPK1KDM4E | |
| SCHEMBL3669791 | 0.91 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2GAAMAPK1KDM4E | |
| SCHEMBL22290361 | 0.88 | SMN1; SMN2 (0.54) | ALDH1A1SMN1; SMN2NPSR1POLBNPC1 | |
| SCHEMBL11478559 | 0.82 | SMN1; SMN2 (0.65) | ALDH1A1SMN1; SMN2GAAMAPK1KDM4E | |
| SCHEMBL1697463 | 0.81 | ALDH1A1 (1.00) | ALDH1A1SMN1; SMN2GAAMAPK1KDM4E | |
| SCHEMBL2747664 | 0.81 | ALDH1A1 (1.00) | ALDH1A1SMN1; SMN2GAAMAPK1KDM4E | |
| SCHEMBL5259296 | 0.81 | ALDH1A1 (1.00) | ALDH1A1SMN1; SMN2GAAMAPK1KDM4E | |
| SCHEMBL15085744 | 0.81 | GAA (0.58) | ALDH1A1SMN1; SMN2GAAMAPK1KDM4E | |
| SCHEMBL5697162 | 0.81 | ALDH1A1 (0.63) | ALDH1A1SMN1; SMN2GAAMAPK1KDM4E | |
| SCHEMBL5792711 | 0.79 | KDM4E (0.50) | ALDH1A1SMN1; SMN2GAAKDM4ECHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114920771-A | Novel synthesis process of intermediate of novel oral medicine for overactive bladder | 苏州虞美景盛新药开发有限公司 | 2022-08-19 | — | — | CN | disclosed |
| US-20200190035-A1 | ROCK-INHIBITING COMPOUND AND USES THEREOF | HITGEN INC. (CN) | 2020-06-18 | — | — | US | disclosed |
| CN-106661017-B | Bicyclic or tricyclic heterocyclic compounds | 田边三菱制药株式会社 | 2019-09-24 | — | — | CN | disclosed |
| CN-106661017-A | novel bicyclic or tricyclic heterocyclic compounds | 田边三菱制药株式会社 | 2017-05-10 | — | — | CN | disclosed |
| EP-2470021-B1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME (US) | 2014-10-22 | — | — | EP | disclosed |
| EP-2470021-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | Merck Sharp & Dohme Corp. (US) | 2012-07-04 | — | — | EP | disclosed |
| EP-1680400-A2 | DERIVATIVES OF N-[ PHENYL(PYRROLIDINE-2-YL)METHYL]BENZAMIDE AND N-[ (AZEPAN-2-YL)PHENYLMETHYL]BENZAMIDE, PREPARATION METHOD THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | Sanofi-Aventis (FR) | 2006-07-19 | — | — | EP | disclosed |
| WO-2005037785-A2 | DERIVATIVES OF N-[PHENYL(PYRROLIDINE-2-YL)METHYL]BENZAMIDE AND N-[(AZEPAN-2-YL)PHENYLMETHYL]BENZAMIDE, PREPARATION METHOD THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190035-A1 | ROCK-INHIBITING COMPOUND AND USES THEREOF | ROCK1, ROCK2, RHOA | ALDH1A1 2812/4885SMN1; SMN2 3309/4885GAA 1354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.